CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) today announced that it will host an
Institutional Investor Meeting on Tuesday, October 16, 2018 in Boston,
Massachusetts.
The program will include presentations by Cerus’ executive team covering
the Company’s business strategy and long term revenue growth drivers.
Cerus will also provide a detailed update on its development programs
including the red blood cell system as well as pathogen-reduced
cryoprecipitate. In addition, guest speakers will provide clinical
perspectives on the blood component transfusion industry.
Registration begins at 9:00 a.m. ET with presentations starting at 9:30
a.m. ET and concluding at approximately 12:00 noon ET.
Institutional investors and analysts are invited to attend in person and
are encouraged to register in advance by emailing Investor Relations at ir@cerus.com.
A live webcast of the presentation will be available from the Investor
Relations page of the Cerus web site at http://www.cerus.com/ir.
A replay will be available for approximately two weeks following the
completion of the event.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181002005350/en/
Cerus Corporation
Tim Lee, 925-288-6137
Investor Relations
Director
Source: Cerus Corporation